Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Impairment of oligodendrocyte lineages in spinal muscular atrophy model systems

Ohuchi, Kazukia,b; Funato, Michinorib; Ando, Shioria,b; Inagaki, Satoshia,b; Sato, Arisua,b; Kawase, Chizurub; Seki, Junkob; Nakamura, Shinsukea; Shimazawa, Masamitsua; Kaneko, Hideob; Hara, Hideakia

doi: 10.1097/WNR.0000000000001206
CELLULAR, MOLECULAR AND DEVELOPMENTAL NEUROSCIENCE
Buy
SDC

Survival motor neuron (SMN) deficiency indicates that various cellular processes are impaired in spinal muscular atrophy (SMA). Previous reports have shown that SMN deficiency causes motor neuron degeneration, whereas the numbers of astrocytes and microglia are significantly increased or activated in SMA model systems. Only a few groups have studied the role of oligodendrocyte (OL) lineages such as OL precursor cell and nerve/glial antigen 2 (NG2)-glia in SMA pathology. Our aim in this study was to investigate whether OL lineages are impaired in SMA model systems. We investigated the expression of myelin basic protein (MBP) and NG2, which are OL lineage markers, using SMNΔ7 mice (mSmn−/−, SMN2+/+, SMNΔ7+/+) and cell cultures derived from induced pluripotent stem cells generated from SMA patients. We showed for the first time that the OL lineages, including NG2-positive OL precursor cells and MBP-positive myelinating OLs were impaired in SMNΔ7 mice and induced pluripotent stem cells derived from SMA patients. Notch was involved in the decline of NG2 expression in the spinal cord of SMNΔ7 mice. In addition, pharmacological Notch inhibition promoted MBP-positive OL differentiation in SMNΔ7 mice. These findings indicate that OL differentiation was impaired in SMA, which might be involved in the Notch dysregulation.

aDepartment of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University

bDepartment of Clinical Research, National Hospital Organization, Nagara Medical Center, Gifu, Japan

Correspondence to Hideaki Hara, PhD, RPh, Department of Biofunctional Evaluation, Molecular Pharmacology, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan Tel/fax: +81 58 230 8126; e-mail: hidehara@gifu-pu.ac.jp

Received December 13, 2018

Accepted January 18, 2019

© 2019 Wolters Kluwer Health | Lippincott Williams & Wilkins